abrdn plc Purchases 293,461 Shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL)

abrdn plc increased its stake in Vigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) by 124.9% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 528,472 shares of the company's stock after purchasing an additional 293,461 shares during the quarter. abrdn plc owned about 1.29% of Vigil Neuroscience worth $898,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Walleye Capital LLC grew its position in shares of Vigil Neuroscience by 334.4% in the third quarter. Walleye Capital LLC now owns 119,792 shares of the company's stock valued at $407,000 after purchasing an additional 92,217 shares in the last quarter. Verition Fund Management LLC purchased a new position in shares of Vigil Neuroscience in the third quarter valued at $442,000. Geode Capital Management LLC grew its position in shares of Vigil Neuroscience by 41.9% in the third quarter. Geode Capital Management LLC now owns 226,083 shares of the company's stock valued at $769,000 after purchasing an additional 66,712 shares in the last quarter. Finally, Point72 Asset Management L.P. grew its position in shares of Vigil Neuroscience by 7.7% in the third quarter. Point72 Asset Management L.P. now owns 1,600,000 shares of the company's stock valued at $5,440,000 after purchasing an additional 115,000 shares in the last quarter. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Vigil Neuroscience Stock Up 1.8 %

Shares of Vigil Neuroscience stock traded up $0.05 during trading on Friday, hitting $2.76. 277,465 shares of the stock traded hands, compared to its average volume of 1,888,886. The stock has a market cap of $112.83 million, a price-to-earnings ratio of -1.34 and a beta of 1.84. The firm's fifty day moving average is $2.05 and its 200-day moving average is $2.95. Vigil Neuroscience, Inc. has a 52 week low of $1.49 and a 52 week high of $6.06.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on VIGL shares. Wedbush upped their target price on Vigil Neuroscience from $23.00 to $24.00 and gave the stock an "outperform" rating in a research note on Friday, November 8th. HC Wainwright restated a "buy" rating and issued a $17.00 target price on shares of Vigil Neuroscience in a research note on Thursday, January 23rd. William Blair started coverage on Vigil Neuroscience in a research note on Wednesday, December 4th. They issued an "outperform" rating on the stock. Guggenheim restated a "buy" rating on shares of Vigil Neuroscience in a research note on Friday, January 24th. Finally, JMP Securities restated a "market outperform" rating and issued a $22.00 target price on shares of Vigil Neuroscience in a research note on Tuesday, November 26th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $19.75.

Vigil Neuroscience Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.